Stefan Constantinescu, MD, PhD is Professor of Molecular and Cell Biology at Université catholique de Louvain, de Duve Institute and Member of the Ludwig Institute for Cancer Research. He received his MD and PhD in Virology from the Carol Davila University of Medicine and Pharmacy in Bucharest, and has been trained as a postdoctoral fellow with Professor Harvey F. Lodish at Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (1995-2000.)
In 2000 he started his independent laboratory at the Ludwig Institute for Cancer Research in Brussels where he studies the structure and function of cytokine receptors, Janus kinases and STATs, as well as signalling in normal and pathological blood formation. Since 2009 he is a Full Member (equivalent Full Professor) of the Ludwig Institute and since 2015 a Professor of Cell and Molecular Biology at Université catholique de Louvain. He is also an Internal Consultant in Hematology at Clinique universitaires Saint Luc in Brussels. Starting April 2021 he spends 25% of his time as Senior Group Leader in the Nuffield Department of Medicine at Oxford University, within the Oxford Branch of the Ludwig Institute for Cancer Research.
He has been elected to Membership at the Royal Academy of Medicine of Belgium, the Romanian Academy (Honorary Foreign Member). In 2021 he has been elected President of the Federation of European Academies of Medicine (FEAM) for 3 years (2021-2024). In the same time he has been President of the Royal Academy of Medicine of Belgium during the year of 2022.

Prof. Dr. Timothy Devos received his medical degree from the University of Leuven (KU
Leuven), followed his training in Internal Medicine and Hematology and is staff member of the Hematology Department of the University Hospitals Leuven (UZ Leuven) since 2007. He
obtained a PhD in Immunology in 2008.
He is Associate Professor at this Faculty of Medicine, KU Leuven.
His main fields of interest are Myeloproliferative neoplasms (MPN), blood transfusion and cellular therapies.
Currently, he is board member of the BHS (Belgian Hematology Society) and member of the EHA MPN Scientific Working Party

Research/Professional Experience:
2023 – pres. Assistant Professor, Department of Hematopoietic Biology and Malignancy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2016 – 2023 Post-doctoral Fellow, Laboratory of Dr. Ross Levine, Memorial Sloan Kettering Cancer Center, New York, NY
2020 – 2023 Assistant Attending Level 1, Division of Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY
2018 – 2020 Instructor of Medicine, Division of Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY
2015 – 2018 Fellow, Hematology/Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

2021 – Present Associate Professor, Department of Oncology and Medicine
2016 – Present Director, NOTCH (Normal and Oncologic Tissue Collection Hub)
2022 – Present Chair, Educational Committee, Johns Hopkins University School of Medicine
2018 – 2022 Associate Chair, Educational Committee, Johns Hopkins University School of Medicine
2021 – Present Peer Reviewer, CDMRP, BMFRP Study Section
2020 – Present Peer Reviewer, ASH Scholar Awards, Junior Faculty Study section
2019 – Present Peer Mentor, ASH-a-Palooza Career Development Day
2016 – Present Director, NOTCH (Normal and Oncologic Tissue Collection Hub)
2015 – Present Peer Reviewer, JCI, Nature Communications, Blood, Leukemia, Haematologica, British Journal of Hematology, Plos One
2015 – Present Member, American Association for Cancer Research

Professor Claire Harrison graduated from Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy chief medical officer.
The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. Her work has led to the approval of new therapies such a ruxolitinib, fedratinib, momelotinib and pacritinib. In the past 10 years she has published widely (>250 academic articles).
In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.

Eric Solary is a full-Professor in Hematology at Université Paris-Saclay and a physician scientist in Gustave Roussy Cancer Center (Villejuif, France). A Scientific Director of Gustave Roussy from 2011 to 2020, Eric Solary also presided over the Scientific Committee of Foundation ARC, a charity exclusively dedicated to cancer research, for 10 years before joining the Board of Directors in 2022. He has been in charge of the Coordination and Support Action 4.UNCAN.eu that prepares a European platform to UNderstand CANcer and currently prepares the creation of UNCAN.eu National Nodes. His research focuses on monocyte differentiation and the pathogenesis of chronic myeloid malignancies, with a special interest in chronic myelomonocytic leukemia.

Current Appointments
University
2019 – 2023 Assistant Professor, Johns Hopkins University School of Medicine, Department of Oncology, Division of Hematological Malignancies and Bone Marrow Transplantation, Baltimore, MD
2024 -Present Associate Professor, Johns Hopkins University School of Medicine, Department of Oncology, Division of Hematological Malignancies and Bone Marrow Transplantation, Baltimore, MD
Hospital
2019 – Present Attending Physician, Johns Hopkins Hospital, Baltimore, MD
2019 – 2022 Director, Chimeric Antigen Receptor (CAR) T-cell Therapy for Hematological Malignancies, Johns Hopkins Hospital, Baltimore, MD
2022 – Present Director, Immune Effector Cell (IEC) Therapy, Johns Hopkins Hospital, Baltimore, MD
Other
2019 – 2024 Member, Practice Guidelines Committee, American Society of Transplantation and Cellular Therapy (ASTCT)
2020 – Present Member, Committee on Cellular Therapy, ASTCT
2022 – 2024 Chair, Committee on Education, ASTCT

Dr Andreas Reiter is an Associate Professor and Consultant of Hematology and Oncology at the Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Germany. Dr Reiter’s main research focus lies on pathogenesis, diagnosis and treatment of myeloproliferative neoplasms (MPN). Since 1992, he has been involved in translational research and numerous clinical trials, most recently particularly focusing on treatment of classic MPN and translational research for a better understanding of pathogenesis, diagnosis and treatment of eosinophilia-associated disorders and systemic mastocytosis. Dr Reiter has established a “German Registry for Disorders of Eosinophils and Mast Cells (GREM)”.

1981-83 MD thesis, Department of Biochemistry, University of Zürich, Switzerland
1983-86 Postdoctoral Fellow, Biozentrum, University of Basel, Switzerland
1986-89 Resident in Internal Medicine, University Hospital Basel, Basel, Switzerland
1989-93 Postdoctoral Fellow, Department of Genetics, Harvard Medical School, Boston, MA
1993-2000 SNF-SCORE and Group leader, Biozentrum, University of Basel, Basel, Switzerland
2000-2002 Head, Molecular Hematology-Oncology, German Cancer Research Center (DKFZ)
2002-present Professor of Molecular Medici
Honors and Awards
1997: Prize of the Swiss Society of Hematology
1999: Ellermann-Prize for Hematology
2004: Research Prize of the Cloetta-Foundation
2007: Ham-Wasserman Lecture Award, American Society of Hematology, Atlanta
2008: Hematological Malignancies Award, Bristol-Myers Squibb and Swiss Society of Hematology
2014: Gateway for Cancer Research/Rising Tide Foundation-CCR/SAKK Cancer Research Grant Award 2014
2020: EHA David Grimwade Award 2020, European Hematology Association
2021: Award 2020 of the San Salvatore Foundation

Peter Valent is Professor of Hematology at the Medical University of Vienna and Scientific Director of the Ludwig Boltzmann Institute for Hematology and Oncology. He serves as Coordinator of the European Competence Network on Mastocytosis (ECNM) and of diverse international consensus groups, and runs several Centers of Excellence in myeloid neoplasms (MPN, MDS, AML, CML, SM) in Vienna. A special focus in his research is the identification of novel markers and targets in neoplastic stem cells and the development of stem cell-eradicating drug therapies. Another major focus in his research is the development of improved management and therapy of patients with mast cell disorders, including mastocytosis and mast cell activation syndromes. Valent is a member in diverse Medical Societies, including the American Society of Hematology. He published more than 900 peer-reviewed articles, including numerous review articles, consensus papers, and major text book chapters, lectured widely in Europe and America and received numerous scientific awards.